Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan

Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan

Abstract Background Resistant bacterial infections, particularly those caused by gram-negative pathogens, are associated with high mortality and economic burdens. Ceftolozane/tazobactam demonstrated efficacy comparable to meropenem in patients with ventilated hospital-acquired bacterial pneumonia in...

Full description

Bibliographic Details
Main Authors: Risako Takaya, Nobuyoshi Mori, Eiko Saito, Sachiko Ohde
Format: Article
Language:English
Published: BMC 2024-03-01
Series:BMC Health Services Research
Subjects:
Ceftolozane/tazobactam
Meropenem
Ventilated-hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia
Cost-effectiveness analysis
Online Access:https://doi.org/10.1186/s12913-024-10883-7

Internet

https://doi.org/10.1186/s12913-024-10883-7

Similar Items